Overlap cardiomyopathy – coexistence of hypertrophic and restrictive cardiomyopathy phenotypes in one patient (RCD code: III-2A.1)
Recent data indicate that substantial proportion of cardiomyopathy patients have in fact more than one phenotype, the phenomenon termed as overlap or mixed cardiomyopathy. The molecular mechanisms and pathology as well as clinical management and prognosis of overlap cardiomyopathy is largely unknown and speculative. We report the case of 51-year-old man who was admitted due to progressive intolerance of physical activity with concomitant shortness of breath. He underwent complex cardiological studies, including invasive examinations and endomyocardial biopsy. However, despite exhaustive diagnostic work-up, the final diagnosis is still not one-hundred percent certain, and we eventually diagnosed him with overlap cardiomyopathy as most probably two phenotypes of hypertrophic and restrictive cardiomyopathy coexist. Perhaps, cardiomyopathies are far too complex entities to be easily labeled with one or another term.
Accumulated data on the clinical course of various cardiomyopathies provide numerous evidence on the continuum rather than onceforever diagnosis. JRCD 2014; 1 (6): 21–28
Elliot PM, Anderson B, Arbustini A, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2007; 29: 270–277.
Kohli SK, Pantazis AA, Shah JS, et al. Diagnosis of left ventricular non‑compaction in patients with left ventricular systolic dysfunction: time of a reappraisal of diagnostic criteria? Eur Hear J 2008; 29: 89–95.
Romero AJ, Perez‑Sanchez I, Redondo B, et al. Mixed cardiomyopathy: implications in family screening of inherited cardiomyopathies. Presentation during ESC 2013 Congress in Amsterdam.
Tiso N, Stephan DA, Naca A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189–194.
Bhuiyan ZA, van den Berg MP, van Tintelen JP, et al. Expanding spectrum of human RYR2‑related disease: new electrocardiographic, structural, and genetic features. Circulation 2007; 116: 1569–1576.
Schoonderwoerd BA, Wiesfeld AC, Wilde AA, et al. A family with
Andersen‑Tawil syndrome and dilated cardiomyopathy. Heart Rhythm 2006; 3: 1346–1350.
Gossios TD, Lopes LR, Elliot PM. Left ventricular hypertrophy caused by a novel nonsense mutation in FHL1. Eur J Med Genet 2013; 56: 252–255.
Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005; 293: 447–454.
Frustaci A, Priori SG, Pieroni M, et al. Cardiac histological substrate in patients with clinical phentype of Brugada syndrome. Circulation 2005; 112: 3680–3687.
Rubiś P, Miszalski‑Jamka T, Cleland JGF et al. Left ventricular non‑compaction with congenital dia phragmatic hernia causing cardiac dextroposition. J Rare Cardiovasc Dis 2012; 1: 18–23.
Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965–1991.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2761–2796.
Elliot P, Lambiase P, Kumar D [edited by]. Inherited Cardiac Disease. Oxford University Press 2011.
Mogensen J, Arbustini E. Restrictive cardiomyopathy. Curr Opin Cardiol 2009; 24: 214–220.
Rapezzi C, Arbustini E, Caforio ALP, et al. Diagnostic work‑up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 1448–1458.
- There are currently no refbacks.